Affiliations: [a]
School of Pharmacy, Ningxia Medical University, Yinchuan, China
| [b]
Department of Pharmacy, People’s Hospital of Ningxia /First Affiliated Hospital of Northwest University for Nationalities, Yinchuan, China
| [c]
Laboratory Department, Clinical college of Ningxia Medical University, Yinchuan, China
| [d]
Department of Pharmacology, Hainan Medical University, Haikou, China
Correspondence:
[*]
Correspondence to: Rui Wang, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China. E-mail: [email protected].
Abstract: Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases worldwide. The accumulation of amyloid-β (Aβ) protein and plaque formation in the brain are two major causes of AD. Interestingly, growing evidence demonstrates that the gut flora can alleviate AD by affecting amyloid production and metabolism. However, the underlying mechanism remains largely unknown. This review will discuss the possible association between the gut flora and Aβ in an attempt to provide novel therapeutic directions for AD treatment based on the regulatory effect of Aβ on the gut flora.
